Skip to main content
. 2019 May 23;63(6):e00126-19. doi: 10.1128/AAC.00126-19

TABLE 2.

PTAs at PD surrogate indices for fosfomycin and meropenem against non-MBL- and MBL-producing P. aeruginosa clinical isolates by dosing regimen for monotherapy and combination therapya

Antimicrobial and regimen Total daily dose (g) MIC50/MIC90 (μg/ml)
PTA (%)
Monotherapy
Combination therapy
Monotherapy Combination therapy MIC50 MIC90 MIC50 MIC90
Fosfomycin 128/512 16/64
    4 g i.v. q8h 12 0 0 89 16
    4 g i.v. q6h 16 0.4 0 94 33
    6 g i.v. q8h 18 3.1 0 96 46
    8 g i.v. q8h 24 16 0 98 64
Meropenem (0.5-h infusion) 16/512 2/64
    1 g q8h 3 61 0 98 2.5
    1.5 g q6h 6 87 0 99 14
    2 g q8h 6 85 0 99 21
Meropenem (3-h infusion)
    1 g q8h 3 67 0 99 4.1
    1.5 g q6h 6 91 0 100 13
    2 g q8h 6 88 0 100 22
a

The pharmacodynamic surrogate index for fosfomycin was an fAUC/MIC of 40.8 for a CLCR of >40 ml/min, and that for meropenem was an ƒT>MIC of 40% for a CLCR of >50 ml/min.